GE Healthcare announced that DaTscan (Ioflupane I 123 Injection) is available for the detection of dopamine transporters (DaT) in the brains of adult patients with suspected Parkinsonian syndromes. DaTscan is a schedule C-II controlled substance radiopharmaceutical imaging agent that works by binding to DaT in the brain that is used for single photon emission computed tomography (SPECT) imaging.
DaTscan may enable appropriate management for patients who have signs or symptoms of Parkinsonian syndromes, by aiding timely, appropriate diagnosis. It may be used as an adjunct to other diagnostic evaluations to help differentiate essential tremor from tremor due to Parkinsonian syndromes, but DaTscan cannot differentiate between the different types of Parkinsonian syndromes.
For more information visit www.datscan.com.